 MeiraGTx Holdings plc MGTX, a vertically integrated, clinical stage gene therapy company, today announced that clinical data updates from the Companys Phase 12 trial of AAV-RPE65 will be presented at two upcoming medical meetings. The Phase 12 open-label, multi-center, dose-finding trial evaluated AAV-RPE65 in patients with retinal dystrophy associated with disease-causing variants in the RPE65 gene, a condition that causes severe sight impairment beginning at birth. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to treat RPE65-deficiency, and optimized for transduction efficiency, potency and stability. 